Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.70 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.64 |
| ▸ | TNKS | O95271 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.64 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.64 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.64 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.64 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.64 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.64 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 0.64 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.64 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.64 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.64 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.64 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.64 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29403857 | 1.00 | PARP1 (0.70) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL19367085 | 1.00 | PARP1 (0.70) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL29466162 | 1.00 | PARP1 (0.70) | PARP1PARP3TNKSADORA1CDK6 | |
| Water SCHEMBL28136735 | 0.98 | PARP1 (0.68) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL23378058 | 0.89 | PARP1 (0.67) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL31621079 | 0.89 | PARP1 (0.65) | PARP1 | |
| SCHEMBL28498791 | 0.89 | PARP1 (0.67) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL8013881 | 0.89 | PARP1 (0.72) | PARP1 | |
| SCHEMBL22852705 | 0.89 | PARP1 (0.74) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL31621083 | 0.89 | PARP1 (0.65) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 382 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504196-B1 | PROCESSES FOR PREPARING OLAPARIB | SCINOPHARM TAIWAN LTD (TW) | 2026-04-08 | — | — | EP | claimed |
| CN-118206598-A | Rhodiola rosea glycoside derivative and preparation method and application thereof | 中国药科大学 | 2024-06-18 | — | — | CN | claimed |
| CN-113603647-B | PARP inhibitor-alkylation bifunctional molecule and preparation method and application thereof | 潍坊医学院 | 2023-01-31 | — | — | CN | claimed |
| CN-113024516-B | Double-target PARP/EZH2 inhibitor, preparation method and application | 中国药科大学 | 2022-05-17 | — | — | CN | claimed |
| CN-114249695-A | Novel crystal form of olaparide, preparation method and application | 齐鲁制药有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-112661702-B | Olaparib impurity and preparation method thereof | 南京方生和医药科技有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-113603647-A | PARP inhibitor-alkylation bifunctional molecule and preparation method and application thereof | 潍坊医学院 | 2021-11-05 | — | — | CN | claimed |
| US-11160803-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2021-11-02 | — | — | US | claimed |
| CN-113234024-A | Novel preparation method of olapari | 北京迈索化学技术有限公司 | 2021-08-10 | — | — | CN | claimed |
| CN-109563080-B | Preparation method of olaparib | 台湾神隆股份有限公司 | 2021-07-30 | — | — | CN | claimed |
| CN-103172619-A | 4-(substituted benzyl)-1(2H)-2,3-phthalazinone derivatives, and preparation methods, medicinal compositions and uses thereof | QILU PHARMACEUTICAL CO LTD | 2013-06-26 | — | — | CN | claimed |
| US-8247416-B2 | Phthalazinone derivative | KUDOS PHARMACEUTICALS LIMITED (GB) | 2012-08-21 | — | — | US | claimed |
| CN-102627611-A | Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | KUDOS PHARM LTD | 2012-08-08 | — | — | CN | claimed |
| EP-2374800-A2 | Methods for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Kudos Pharmaceuticals Limited (GB) | 2011-10-12 | — | — | EP | claimed |
| US-7692006-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-06 | — | — | US | claimed |
| US-20090270617-A1 | PHTHALAZINONE DERIVATIVE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-10-29 | — | — | US | claimed |
| CN-101528714-A | Polymorphs of 4- [ 3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4-fluoro-benzyl ] -2H-phthalazin-1-one | KUDOS PHARM LTD (GB) | 2009-09-09 | — | — | CN | claimed |
| EP-2064189-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | Kudos Pharmaceuticals Limited (GB) | 2009-06-03 | — | — | EP | claimed |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | claimed |
| WO-2008047082-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160803-B2 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | PARP1 3029/4885PARP3 3491/4885TNKS 4048/4885 |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | PARP1, PARP11, PARP2 | PARP1 1/4885PARP3 4/4885TNKS 129/4885 |
| US-20090270617-A1 | PHTHALAZINONE DERIVATIVE | PML, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA4 | PARP1 379/4885PARP3 1682/4885TNKS 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.